An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
Zhonghua Yi Xue Za Zhi (Taipei)
; 58(4): 264-8, 1996 Oct.
Article
em En
| MEDLINE
| ID: mdl-8994331
ABSTRACT
BACKGROUND:
To improve dose-related fluctuations in patients with Parkinson's disease, the efficacy of selegiline, a selective inhibitor of monoamine oxidase B, was determined.METHODS:
Twenty parkinsonian patients were selected for a short-term, single-blind, cross-over trial. Each patient received one of the two brands of selegiline, Parkryl (Mei-Shih), 10 mg per day as an adjunct to Madopar. After a 6-week treatment period and a 4-week wash-out period, the treatment was switched to the other brand of selegiline, Jumexal (Labatec), for another 6 weeks.RESULTS:
Five patients dropped out of the study because of the development of intolerable dyskinesia, hallucination or agitation. The 15 patients that completed the study made a mild improvement in the total motor scores of the on-period during both treatments of Parkryl (p < 0.01) and of Jumexal (p < 0.05). The recorded daily off-time decreased from 37.8% to 20.7% in the Parkryl group (p < 0.01), and to 21.0% in the Jumexal group (p < 0.01).CONCLUSION:
Selegiline, as an adjunct therapy to Madopar, has a moderate effect in prolonging the duration of on-time in parkinsonian patients with dose-related fluctuations. Jumexal seemed to produce no greater effect than Parkryl.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Selegilina
/
Benserazida
/
Levodopa
/
Inibidores Enzimáticos
/
Movimento
/
Antiparkinsonianos
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
1996
Tipo de documento:
Article